8th Kuopio Alzheimer Symposium
From translational research to biomarkers, treatment and prevention strategies

Thursday, June 7
Opening and keynote session
Chairpersons: Mikko Hiltunen and Miia Kivipelto
09:00-10:00 Registration
10:00-10:05 Opening words
Mikko Hiltunen, Chair of the Organizing Committee
10:05-10:15 Welcome address
Jorma Palvimo, Vice-Dean of the Faculty of Health Sciences, UEF, Kuopio, Finland
10:15-10:30 Welcome address
Sirpa Pietiläinen, Member of European Parliament
10:30-11:15 Keynote lecture 1: Highlights of clinical Alzheimer research
Hilkka Soininen, University of Eastern Finland
11:15-12:00 Keynote lecture 2: Converging approaches to the development of anti-apoE4 therapy
Daniel Michaelson, Rabin Institute of Neurobiology, Tel Aviv University, Israel
12:00-12:10 Neurocenter Finland - promoting neuroscience and innovation
Mikael von und zu Fraunberg, Director of Neurocenter Finland, Kuopio, Finland
12:10-13:00 Lunch break

I Scientific session - Translational research of neurodegeneration in Alzheimer’s disease and other neurodegenerative diseases
Chairpersons: Mikko Hiltunen and Tarja Malm
13:00-13:25 Multiscale translational in vivo imaging in Alzheimers disease
Vesa Kiviniemi, Oulu University Hospital, Finland
13:25-13:50 PSEN1 mutant iPSC-derived model reveals severe astrocyte pathology in Alzheimer’s disease
Jari Koistinaho, Helsinki University/UEF, Kuopio, Finland
13:50-14:15 NMDA receptors and calcium in early synaptic dysfunction
Luísa Lopes, Instituto de Medicina Molecular, Lisbon, Portugal
14:15-14:40 BACE-1 inhibitor CNP520 for prevention studies in Alzheimer’s disease
Ulf Neumann, Novartis Institute for Biomedical Research, Basel, Switzerland
14:40-15:05 Early role of dipeptide repeat proteins in C9or72 ALS/FTD
Dieter Edbauer, DZNE, Munich, Germany
15:05-16:00 Coffee break

II Scientific session - New developments in diagnostic and predictive biomarkers in Alzheimer’s disease and other neurodegenerative diseases
Chairpersons: Anne Remes and Martin Ingelsson
16:00-16:25 CSF automated biomarker assays and their implication for Alzheimer’s disease management
Maryline Simon, Roche, Basel, Switzerland
16:25-16:50 Novel CSF fragments of tau: candidate biomarkers for Alzheimer’s disease and tauopathies
Kina Höglund, University of Gothenburg, Sweden
16:50-17:15 Improved discrimination between healthy control subjects and patients with cognitive decline by integrating ELISA and mass spectrometry-based cerebrospinal fluid biomarkers
Martin Ingelsson, Uppsala University, Sweden
17:15-17:40 Diagnostic and predictive markers of predementia AD: the EMIF-AD biomarker discovery study
Pieter Jelle Visser, University of Amsterdam, the Netherlands
20:00-22:30 Get-together party and poster session (Scandic Ballroom, Satamakatu 1)
Friday, June 8

III Scientific session - New technologies in neurodegenerative diseases, including imaging, disease models and neuroinformatics
Chairpersons: Juha Rinne and Jari Koistinaho
08:00-08:30 Registration
08:30-08:55 Midlife insulin resistance and late-life cognition, brain amyloid accumulation, and cerebrovascular lesions
Laura Ekblad, Turku University Hospital, Finland
08:55-09:20 Clinical decision support in diagnosing neurodegenerative diseases
Jyrki Lötjönen, Combinostics, Tampere, Finland
09:20-09:45 The potential of low-cost tests for decision support in neurodegenerative diseases
Mark van Gils, VTT Technical Research Centre of Finland Ltd, Finland
09:45-10:10 3D human neural cell culture models of Alzheimer’s disease: towards a cure-in-a-dish?
Doo Yeon Kim, MGH/Harvard Medical School, Charlestown, MA, USA
10:10-10:35 Zooming in on alpha-synuclein aggregation: imaging super-powers
Tiago Outeiro, University Medical Center Gottingen, Germany
10:35-11:00 Coffee break

IV Scientific session - Co-morbidities of neurodegenerative diseases
Chairpersons: Annakaisa Haapasalo and Wiesje van der Flier
11:00-11:25 Advances in Alzheimer’s diagnosis; implications for clinical practice
Wiesje van der Flier, University of Amsterdam, Netherlands
11:25-11:50 NPH Dementia
Ville Leinonen, UEF/Oulu University Hospital, Kuopio, Finland
11:50-12:15 Idiopathic normal pressure hydrocephalus and Alzheimer’s disease: differential diagnosis and co-occurrence
Etsuro Mori, Tohoku University, Japan
12:15-12:40 Quantifying dementia risk and prevention potential in clinical trials
Alina Solomon, UEF/Karolinska Institutet, Stockholm, Sweden
12:40-13:05 Common molecular mechanisms of Alzheimer’s disease and Type-2 diabetes
Mikko Hiltunen, UEF, Kuopio, Finland
13:05-14:00 Lunch break

V Scientific session - Prevention and therapies of neurodegenerative diseases
Chairpersons: Miia Kivipelto and Ingmar Skoog
14:00-14:25 Multi-domain interventions to prevent dementia: from FINGER to World-Wide FINGERS
Miia Kivipelto, Karolinska Institutet, Stockholm, Sweden
14:25-14:50 Preclinical Alzheimer’s disease - Implications for prevention and treatment
Ingmar Skoog, University of Gothenburg, Sweden
14:50-15:15 Prevention and therapy for neurodegenerative disease: Asian perspectives
Christopher Chen, University of Singapore, Singapore
15:15-15:40 Adherence to multidomain preventive interventions and experiences from real-life implementation
Tiia Ngandu, National Institute for Health and Welfare, Helsinki, Finland
15:40-16:05 New treatment strategies to fight Alzheimer’s disease or waiting for Godot
Nenad Bogdanovic, Karolinska University Hospital, Stockholm, Sweden
16:05-16:30 Health economic aspects of dementia prevention
Anders Wimo, Karolinska Institutet, Stockholm, Sweden
16:30-16:40 Closing remarks
Hilkka Soininen, UEF, Kuopio, Finland